Jeffrey Thompson - Anika Therapeutics Independent Director
| ANIK Stock | USD 25.97 0.40 1.56% |
Director
Mr. Jeffrey S. Thompson is an Independent Director of Anika Therapeutics Inc. He is a Partner with HealthEdge Investment Partners, LLC, a Tampa, Florida based private equity firm that provides strategic capital exclusively in the healthcare industry. Mr. Thompson currently serves as a director for various HealthEdge affiliated companies including AMC, Formulated Solutions, Santus, MNG Laboratories, Columbus Group, and Data Dimensions, LLC. Mr. Thompson also serves as a nonexecutive director for Sinclair Pharma, plc, a publicly traded, Londonbased, international aesthetic dermatology company. Prior to joining Anika, he served as President, Chief Executive Officer and Chairman of Advanced BioTechnologies and Enaltus, HealthEdge portfolio companies specializing in skincare solutions. Mr. Thompson also served as a director and the Chief Operating Officer for Stiefel Laboratories, Inc., an independent pharmaceutical company specializing in dermatology. Prior to his Chief Operating Officer role, he was Stiefels Senior Vice President of U.S. Business Services and President of Glades Pharmaceuticals. Earlier in his career, Mr. Thompson held sales and business management positions at Bausch Lomb Pharmaceuticals and SmithKline Beecham since 2011.
| Age | 51 |
| Tenure | 13 years |
| Address | 32 Wiggins Avenue, Bedford, MA, United States, 01730 |
| Phone | 781 457 9000 |
| Web | https://www.anika.com |
Jeffrey Thompson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Thompson against Anika Therapeutics stock is an integral part of due diligence when investing in Anika Therapeutics. Jeffrey Thompson insider activity provides valuable insight into whether Anika Therapeutics is net buyers or sellers over its current business cycle. Note, Anika Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anika Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Thompson over three months ago Bona fide gift to Jeffrey Thompson of 38367 shares of Red Cat subject to Section 16 | ||
Jeffrey Thompson over six months ago Purchase by Jeffrey Thompson of 500 shares of Red Cat |
Anika Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0236) % which means that it has lost $0.0236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3321) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.3 this year. Return On Capital Employed is expected to rise to -0.1 this year. At this time, Anika Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 148 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jose Bedoya | SurModics | 61 | |
| Robert Rudelius | Axogen Inc | 62 | |
| Carlton Highsmith | Paragon 28 | 63 | |
| Heidi Kunz | Avanos Medical | 66 | |
| Anthony Martin | Orthofix Medical | 59 | |
| Quentin Blackford | Axogen Inc | 39 | |
| Thomas Bowers | Paragon 28 | 70 | |
| William Hawkins | Avanos Medical | 65 | |
| John Byrnes | Avanos Medical | 62 | |
| Michael Paolucci | Orthofix Medical | 57 | |
| Julie Shimer | Avanos Medical | 68 | |
| Patrick OLeary | Avanos Medical | 63 | |
| Stephen Burns | Orthopediatrics Corp | 74 | |
| Bryan Hughes | Orthopediatrics Corp | 40 | |
| Harald Ruf | Orthopediatrics Corp | 64 | |
| Carl Florio | Paragon 28 | 64 | |
| Susan Harnett | Paragon 28 | 57 | |
| David Dantzker | SurModics | 74 | |
| David Pelizzon | Orthopediatrics Corp | 62 | |
| Alan Kozlowski | Orthopediatrics Corp | 51 | |
| John Benson | SurModics | 69 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0236 |
Anika Therapeutics Leadership Team
Elected by the shareholders, the Anika Therapeutics' board of directors comprises two types of representatives: Anika Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anika. The board's role is to monitor Anika Therapeutics' management team and ensure that shareholders' interests are well served. Anika Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anika Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Sherwood, CEO and President and Director | ||
| James Chase, Senior Marketing | ||
| Bart Bracy, VP Americas | ||
| Lisa Funiciello, Vice Resources | ||
| Mark Namaroff, Executive Communications | ||
| Dana Alexander, COO | ||
| Raymond Land, Independent Director | ||
| Richard Hague, Chief Commercial Officer | ||
| Susan Vogt, Independent Director | ||
| Michael Levitz, CFO VP | ||
| Ben Joseph, Vice Development | ||
| Joseph Darling, President | ||
| Sylvia Cheung, CFO, Principal Accounting Officer, Treasurer and Secretary | ||
| Joseph Bower, Lead Independent Director | ||
| Jeffrey Thompson, Independent Director | ||
| David Colleran, Gen VP | ||
| David JD, General VP | ||
| Steven Wheeler, Independent Director | ||
| Thomas Finnerty, Chief Human Resource Officer | ||
| Stephen Mascioli, Chief Medical Officer | ||
| Edward Ahn, Chief Technology and Strategy Officer | ||
| Ian McLeod, VP Officer | ||
| Charles III, VP Counsel | ||
| Glenn Larsen, Independent Director | ||
| Anne Nunes, VP Operations | ||
| Cheryl Blanchard, Independent Director |
Anika Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anika Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0236 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 331.08 M | ||||
| Shares Outstanding | 14.85 M | ||||
| Shares Owned By Insiders | 3.25 % | ||||
| Shares Owned By Institutions | 94.31 % | ||||
| Number Of Shares Shorted | 811.11 K | ||||
| Price To Earning | 42.30 X |
Pair Trading with Anika Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Anika Stock
| 0.58 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
| 0.56 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.54 | EVOK | Evoke Pharma | PairCorr |
| 0.48 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Anika Stock analysis
When running Anika Therapeutics' price analysis, check to measure Anika Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anika Therapeutics is operating at the current time. Most of Anika Therapeutics' value examination focuses on studying past and present price action to predict the probability of Anika Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anika Therapeutics' price. Additionally, you may evaluate how the addition of Anika Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Anika Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (5.64) | Revenue Per Share 11.372 | Quarterly Revenue Growth 0.085 | Return On Assets (0.02) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.